Logo-jrip
Submitted: 27 Jul 2023
Accepted: 26 Sep 2023
ePublished: 01 Oct 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2023;12(4): e32247.
doi: 10.34172/jrip.2023.32247

Scopus ID: 85174735828
  Abstract View: 966
  PDF Download: 1455

Review

Renal dysfunction in individuals with ovarian cancer; a review on current concepts

Azadeh Yousefnezhad 1 ORCID logo, Seyedeh Reyhaneh Yousefi Sharemi 2 ORCID logo, Elham Saffarieh 3 ORCID logo, Fahimeh Nokhostin 4* ORCID logo

1 Department of Obstetrics and Gynecology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Obstetrics and Gynecology, Kurdistan University of Medical Sciences, Sanandaj, Iran
3 Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran
4 Department of Obstetrics and Gynecology, Faculty of Medicine, Shahid Sadughi University of Medical Sciences, Yazd, Iran
*Corresponding Author: Fahimeh Nokhostin, Email: Fahimeh.nokhostin@yahoo.com

Abstract

Renal impairment is a common complication in patients with ovarian cancer. Renal impairment in ovarian cancer patients can be caused by various factors. Many of the chemotherapeutic agents administered to treat ovarian cancer are nephrotoxic and can promote kidney dysfunction, leading to renal impairment. Ovarian tumors can obstruct the urinary tract, leading to a reduction in renal function and dilation of the upper urinary tract. Acute kidney injury (AKI) can occur in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Women treated for epithelial ovarian cancer suffer an accelerated rate of renal function decline, independent of major risk factors for kidney disease. Conversely, renal impairment can affect the dosage of chemotherapy drugs used in ovarian cancer treatment. Dose reduction, dose adjustment based on pharmacokinetic data, alternative treatment regimens, and individualized dosing may be necessary to ensure optimal therapeutic outcomes while minimizing the risk of toxicity and treatment-related complications.

Implication for health policy/practice/research/medical education:

Renal impairment is a common complication in patients with ovarian cancer. Kidney dysfunction following ovarian cancer can be caused by a variety of factors, including tumor obstruction, chemotherapy toxicity, and dehydration. Patients with ovarian cancer who develop renal impairment may experience symptoms such as fatigue, nausea, vomiting, and swelling in the legs and feet. Treatment options for renal impairment in these patients may include hydration therapy, and medications to manage electrolyte imbalances. In addition to managing the symptoms of renal impairment, it is important to address the underlying cause of the condition. For example, if the impairment is caused by tumor obstruction, surgery or radiation therapy may be necessary to remove or shrink the tumor.

Please cite this paper as: Yousefnezhad A, Yousefi Sharemi SR, Saffarieh E, Nokhostin F. Renal dysfunction in individuals with ovarian cancer; a review on current concepts. J Renal Inj Prev. 2023; 12(4): e32247. doi: 10.34172/jrip.2023.32247.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 967

Your browser does not support the canvas element.


PDF Download: 1455

Your browser does not support the canvas element.